NCT04015648View on ClinicalTrials.gov

Safety and Immunogenicity of a Candidate ZIKV Vaccine (ZIKA001)

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

October 21, 2019

Primary Completion Date

March 10, 2022

Study Completion Date

March 10, 2022

Conditions
Zika
Interventions
BIOLOGICAL

ChAdOx1 Zika

Single dose of ChAdOx1 Zika at different concentrations: 5 x 10\^9 vp, 2.5 x 10\^10 vp, 5 x 10\^10 vp

Trial Locations (1)

OX3 7LE

CCVTM, University of Oxford, Churchill Hospital, Oxford

All Listed Sponsors
lead

University of Oxford

OTHER

NCT04015648 - Safety and Immunogenicity of a Candidate ZIKV Vaccine (ZIKA001) | Biotech Hunter | Biotech Hunter